Proactive Monitoring of Remicade Levels in IBD Patients May Decrease Risk of Hospitalization, Study Finds

Proactive Monitoring of Remicade Levels in IBD Patients May Decrease Risk of Hospitalization, Study Finds
Proactive monitoring of the levels of Remicade (infliximab) in patients with inflammatory bowel disease (IBD) may help promote patients' health and decrease their hospital visits, according to scientists from the Center for Inflammatory Bowel Disease at the Beth Israel Deaconess Medical Center (BIDMC) and the University of Pennsylvania. The study, "Proactive Compared to Reactive Therapeutic Drug Monitoring for Optimizing Infliximab Maintenance Therapy is Associated with Less IBD-Related Surgery and Hospitalization," was published in the journal Clinical Gastroenterology and Hepatology. Janssen's Remicade is a common first-line therapy used to treat IBD, but up to half the patients eventually stop responding to the drug. At this stage, clinicians often start to monitor patients' blood to assess the drug concentration. In their study, researchers observed that continuous monitoring of patients treated with Remicade is associated with improved long-term outcomes compared to patients who started monitoring only after the drug lost its effectiveness. "IBD can lead to serious complications and a high rate of surgery despite medical therapy," Adam S. Cheifetz, MD, the study's lead author and director of the Center for Inflammatory Bowel Disease at the BIDMC, s
Subscribe or to access all post and page content.

One comment

  1. I wonder if the “control” group showed up for regular “sham” blood tests (just not TDM) on the same schedule as the “proactive” group. There are, after all, some benefits to regular office visits, which by the way are a good marker of patients’ motivation and adherence!

Leave a Comment

Your email address will not be published. Required fields are marked *